Current Report Filing (8-k)
30 August 2017 - 7:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
August
29, 2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
(250)
765-6424
N/A
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
[ ]
- 2 -
Item 3.02
Unregistered Sales of Equity Securities
On August 29, 2017, Lexaria Bioscience Corp. (the Company or
Lexaria) announced it is attending and exhibiting at the Investorshub
International Cannabis Conference in Los Angeles on September 1-2, held at the
JW Marriott downtown. Chris Bunka, CEO of Lexaria, will be giving a presentation
on the latest technology available to benefit the cannabis industry.
On September 7-8, Lexaria is attending and exhibiting at The
Institutional Capital & Cannabis Conference (East) in Miami Beach. This
conference is targeted at high net worth investors, family offices and
institutions as an East Coast follow up to an earlier sold-out event in
California.
Lexaria has also received and executed a notice of conversion
related to certain convertible debt, extinguishing a $45,000 convertible debt
plus interest for 307,500 restricted common shares at the contracted conversion
price of US$0.15. Lexaria has also issued 32,433 common shares to settle
US$12,000 of debt to a director, at a conversion price of US$0.37 per share.
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
Item 7.01
Regulation FD Disclosure
A copy of the news release announcing that Lexaria will be
attending two Cannabis Investment Conferences and Issuing Shares for Debt is
filed as exhibit 99.1 to this current report and is hereby incorporated by
reference.
Item 9.01
Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris
Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: August 30, 2017
|
|